Alto, a pharmacy start-up, just raised $250 million from SoftBank’s Vision Fund 2 and others

CNBC: | January 30, 2020

Alto, a pharmacy start-up, just raised $250 million from SoftBank’s Vision Fund 2 and others
Alto Pharmacy has raised $250 million from investors including SoftBank’s second Vision Fund, three people familiar with the matter told CNBC. The investment has already been approved by the Vision Fund’s investment committee, meaning it’s a done deal, the sources said. It also marks one of the first handful of known bets from the SoftBank’s new fund. The deal values the company at more than $700 million, according to one of the people. SoftBank’s Vision Fund has already done just over half a dozen deals in the health and life sciences sector, including 10x Genomics, which subsequently went public, and employer health-focused Collective Health. It has several venture partners dedicated to the space, with Silicon Valley-based Deep Nishar taking the most active interest in health care.

Spotlight

The best way to dispose of most types of old, unused, unwanted, or expired medicines (both prescription and over the counter) is to drop off the medicine at a drug take back site, location, or program immediately.

Related News

YellowDog Accelerates Drug Discovery from One Year to Less Than One Day with a 162,120 Core Supercomputer, On-Demand

Prnewswire | September 21, 2020

In drug discovery, as with many of the life sciences, data is key. The size of a dataset and the quality of the analyses has a powerful influence on the success of a given drug development programme. There is great potential for the cloud to aid drug discovery, as it offers companies the ability to dynamically scale their research and analyse more data than they would with their on-premise infrastructure. OMass Therapeutics saw an opportunity to accelerate their virtual screening capabilities by utilising Harvard University's REAL database and YellowDog's multi-cloud workload management solution. With access to an on-demand supercomputer, OMass were able to dock 500 times more virtual compounds, and significantly enrich the top 10% of compounds screened. This top-level analysis enabled OMass to focus their attention on the most likely active molecules for their specific drug target.

Read More

Moderna, AstraZeneca and J&J coronavirus shots rev up for NIH tests beginning in July: WSJ

Fiercepharma | June 10, 2020

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson’s shot, a U.S. government researcher told the newspaper. All three of the shots are based on brand-new technologies, and they're all reportedly among finalists in the Operation Warp Speed program. Former FDA chief Scott Gottlieb has publicly questioned the picks, pointing out the team's reliance on new technologies. Johnson & Johnson has not previously disclosed any human testing for its vaccine and the company has previously said it’s aiming to enter human studies in September. But on Wednesday, the company said it's accelerating its timeline, with plans to start a phase 1/2a study in July.

Read More

Trump fulfilled a longstanding campaign promise to lower drug prices

East Idaho News | July 20, 2020

President Donald Trump fulfilled to a longstanding campaign promise Friday — to lower drug prices. He signed four executive orders, including ones on importing medications from Canada and basing the cost of drugs in the US on their prices in other countries — both of which progressive Democrats, including Vermont Sen. Bernie Sanders, have pushed. The efforts, which largely reaffirm the policies of the administration, are unlikely to have an effect before the November election, if they ever do. Most require rule making by the Department of Health and Human Services and could be challenged in court. Notably, however, Trump strongly advocated allowing Medicare to negotiate prices — a measure he slammed House Democrats for including in their drug price bill last December. The Medicare Modernization Act of 2003, which established Medicare’s Part D drug plan, banned such negotiation to secure the votes of Republican lawmakers. “Under our ridiculous system, which has been broken for decades, we aren’t even allowed to negotiate the price of drugs,” Trump said Friday just prior to signing the orders. “Can you imagine? What kind of a system is that? It’s going to end.”

Read More

Spotlight

The best way to dispose of most types of old, unused, unwanted, or expired medicines (both prescription and over the counter) is to drop off the medicine at a drug take back site, location, or program immediately.